Prudential Financial
KYMR icon

Prudential Financial’s Kymera Therapeutics KYMR Stock Holding History

Prudential Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$745K Buy
8,950
+5,540
+162% +$439K ﹤0.01% 1702
2025
Q4 		$265K Sell
3,410
-3,140
-48% -$212K ﹤0.01% 2007
2025
Q3 		$371K Sell
6,550
-57,620
-90% -$2.6M ﹤0.01% 2041
2025
Q2 		$2.8M Sell
64,170
-31,260
-33% -$1.08M ﹤0.01% 1220
2025
Q1 		$2.61M Sell
95,430
-1,387
-1% -$50.6K ﹤0.01% 1168
2024
Q4 		$3.89M Sell
96,817
-25,273
-21% -$1.14M 0.01% 970
2024
Q3 		$5.78M Buy
122,090
+72,370
+146% +$3.2M 0.01% 932
2024
Q2 		$1.48M Buy
49,720
+325
+0.7% +$11.3K ﹤0.01% 1596
2024
Q1 		$1.99M Buy
+49,395
New +$1.77M ﹤0.01% 1452
2022
Q1 		– Sell
-29,695
Closed -$1.92M – 2655
2021
Q4 		$1.92M Buy
29,695
+7,905
+36% +$460K ﹤0.01% 1564
2021
Q3 		$1.28M Buy
21,790
+7,400
+51% +$429K ﹤0.01% 1681
2021
Q2 		$698K Buy
14,390
+1,570
+12% +$68.2K ﹤0.01% 2002
2021
Q1 		$498K Buy
+12,820
New +$772K ﹤0.01% 2134

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Prudential Financial's KYMR Position: Q1 2026 in Review

Prudential Financial increased its Kymera Therapeutics (KYMR) stake by 162% in Q1 2026, buying an estimated $439K and bringing the position to 8,950 shares worth $745K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

Prudential Financial first reported a position in KYMR in Q1 2021 and has held it in 13 quarters since. The position peaked at $5.78M in Q3 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Prudential Financial held 8,950 shares of Kymera Therapeutics worth $745K as of Q1 2026.
  • Prudential Financial bought 5,540 Kymera Therapeutics shares in Q1 2026, an estimated $439K.
  • Kymera Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1702 holding.
  • Prudential Financial first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Prudential Financial's Kymera Therapeutics position peaked at $5.78M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.